1	Association between comorbidities and death from COVID-19 in			
2	different age groups			
3	Pedro Emanuel Fleitas ^{a,b*} , María Cristina Almazán ^{a,b} , Sabrina Daniela Cortez ^b , Jorge Augusto			
4	Paz ^c , Rubén Oscar Cimino ^{a,b} , Alejandro Javier Krolewiecki ^a			
5	a. Instituto de Investigaciones de Enfermedades Tropicales (IIET-CONICET), Universidad			
6	Nacional de Salta. Alvarado 751. San Ramón de la Nueva Orán, Salta, Argentina. ZC:			
7	4530.			
8	b. Cátedra de Química Biológica, Facultad de Ciencias Naturales, Universidad Nacional de			
9	Salta. Avenida Bolivia 5150. Salta, Argentina. ZC: 4400.			
10	c. Instituto de Estudios Laborales y del Desarrollo Económico (IELDE), Consejo Nacional			
11	de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Salta.			
12	Avenida Bolivia 5150. Salta, Argentina. ZC: 4400.			
13				
14	* Corresponding autor: PhD. Pedro E. Fleitas			
15	Mail: pedro.fleittas@gmail.com			
16	Tel: +5493424408448			
17	Work address: Instituto de Investigaciones de Enfermedades Tropicales (IIET). Alvarado 751,			
18	San Ramón de la Nueva Orán, Salta, Argentina. Zip Code: 4530.			
19				

20 Abstract

Background: This new COVID-19 pandemic challenges health systems around the world; therefore, it is extremely important to determine which patients with COVID-19 can evolve to more severe outcomes. Accordingly, we decided to assess the role that comorbidities play in death from COVID-19.

Methods: Two age groups ($<60 \text{ and } \ge 60 \text{ years}$) were defined for analysis. Decision trees were made to identify which comorbidities had the highest fatality rate (FR). Multiple logistic regressions were performed to measure the association between comorbidities and death.

Results: A significant difference was found between the FR of <60 group and ≥ 60 group. The most frequent comorbidity were cardiac diseases and diabetes. The combination of comorbidities with the highest FR was diabetes with kidney disease. Combinations of more than two comorbidities presented higher FR. The comorbidities had higher Odd ratios in the younger group than in the older group.

33 Conclusions: Comorbidities seem to play a greater role in death from COVID-19 in the younger 34 group, while in the> 60 group; age seems to be the most important factor. We assigned a score to 35 the comorbidities and their combinations for both age groups to help the health personnel make 36 decisions.

37 Keywords

38 COVID-19; Comorbidities; Fatality rate; Score

40 Introduction

From the first case of COVID-19 that was reported in the city of Wuhan, China in December 41 2019 until the beginning of November 2020, 46 million infected people have been reported 42 worldwide.¹ Of these 46 million, 2.6% have died.¹ This new pandemic challenges health systems 43 around the world and carries important ethical questions, especially under the need of rationing 44 health care in the context of scarce resources and crisis capacity.² For this reason, it is extremely 45 important to determine which patients with COVID-19 can evolve to more severe outcomes, 46 including death. Age, male gender, and ethnicity have all been reported to be associated with 47 severe COVID-19 outcomes.^{3,4} Also, comorbidities such as diabetes, kidney, respiratory, and 48 cardiovascular diseases have been reported as risk factors for severe outcomes by COVID-19.^{3,5} 49 Based on this, we decided to assess the role that comorbidities play in death from COVID-19 in a 50 large database from Brazil that includes recovered and deceased patients, to provide valuable 51 information for designing strategies for case management. 52

53 Material and methods

54 Data source

The data file was downloaded from the website of the Brazilian Ministry of Health on August 1, 2020. ⁶ The data comes from the e-SUS NOTIFICA system, which was developed to register suspected cases of COVID-19 in Brazil, and contains patient information such as place of residence, clinical, demographic, and epidemiological characteristics. An *ad-hoc* database was built for this project with all laboratory confirmed positive cases (RT-PCR or serology) or clinical-epidemiological survey containing information on date of onset of symptoms, date of the diagnostic test, age, sex, and disease evolution. Patients with missing data were excluded from
the database. We did not impose any further exclusion criteria to limit selection bias.

63 Study design

Two age-group were defined for the analysis with those <60 or ≥ 60 years-old. Decision trees 64 were built to order the comorbidities according to their frequency and the proportion of deaths 65 66 from COVID-19 reported. Then, the correlation of the absence/presence of the following 67 comorbidities: diabetes, immunosuppression, kidney, respiratory, and cardiovascular disease with death from COVID-19 was analyzed. For this, a multiple logistic regression was performed to 68 69 identify which variables were associated with death from COVID-19. Also, the probability obtained from logistic regressions (probability of dying when infected by COVID-19 if the 70 comorbidities were present) was used to calculate the area under the receiver-operator 71 72 characteristic curve (AUC). The AUC was used as a measure of the ability of the comorbidities model to predict death from COVID-19. Finally, the values of probability obtained from logistic 73 regressions were used to assign a score to the comorbidities and the combinations of them. All 74 statistical analyses were carried with RStudio version 1.3.1093 (RStudio: Integrated 75 Development for R. RStudio, PBC, Boston, MA). Analyses with p-values <0.05 for a level of 76 77 significance of 95% were considered statistically significant. Figures were done with GraphPad 78 Prime 9 Trial version (GraphPad Software Inc., San Diego, CA).

79 **Results**

80 Data description

The whole database includes over 8 million cases recorded in the 27 states of Brazil from January 1 to August 1 2020, 549733 were included in the analysis (Fig. 1). A summary of the

comorbidities registered in all the patients can be observed in Table S1 of supplementary material. In our database, median age was 38 years old (IQR: 30-51); 46% were males and 54% females. It was found that 2.1% of patients died while 97.9% were recovered. A statistically significant difference was found between the fatality rate of <60 group (0.7%, n= 457557) and \geq 60 group (11.3% n= 74176) (p<0.01) (Fig. 2). Also, the median time between the onset of symptoms and death was 20 days (IQR: 12-33), and no differences were found between age groups.

Five comorbidities were recorded in the data file: cardiovascular disease, immunosuppression, 90 kidney disease, respiratory disease, and diabetes. Among 87.6% of the cases, no comorbidities 91 were registered; meanwhile, the most frequent comorbidity registered in the database was 92 cardiovascular disease (7.2% (39542/549733)), followed by diabetes (4.3% (23966/549733)), 93 respiratory disease (2.0% (11035/549733)), immunosuppression (0.9% (4934/549733)) and 94 kidney disease (0.5% (2684/549733)). In addition, It was observed that in the <60 group, cardiac 95 disease (Frequency= 4.3%) and diabetes (Frequency= 2.6%) presented a fatality rate of 1.6% and 96 97 0.5% (Fig. 3a). In addition, the highest fatality rate (19%) was found in individuals with diabetes and kidney disease (Fig. 3a). In the ≥ 60 group the most frequent comorbidities were also diabetes 98 99 (Frequency =15%, fatality rate =19%) and cardiovascular disease, without diabetes, (Frequency 100 =12.4%, fatality rate =13%). At the same time, the combination of comorbidities with the highest fatality rate was diabetes with kidney disease (fatality rate= 35%) and diabetes with kidney and 101 102 respiratory diseases (fatality rate= 47%) (Fig. 3b).

103

105	Figure 1: Flowchart of data used in this study. *According to Guidelines for Case Notification of
106	Influenza Syndrome suspected of COVID-19. ⁷
107	
108	Figure 2: Frequency of recovery and death from COVID-19, according to the patient's age.
109	
110	Figure 3: Tree diagrams representing the frequency of the comorbidities and the fatality rate. a.
111	<60 group (n=457557). b. \geq 60 group (n=74176). In each node, its number is represented in the
112	top, and inside the fatality rate (MR) and the percentage frequency (F). DBT= Diabetes, $IS =$
113	immunosuppression, KD = kidney disease, RD = respiratory disease, CD= Cardiovascular
114	disease, P= comorbidity present and A= comorbidity absent.
115	Correlation among comorbidities and death from COVID-19
116	For the <60 group and \geq 60 groups, the values of AUC=0.66 and AUC=0.61 were obtained,
117	respectively. As Fig. 4 shows, the comorbidities had higher ORs in the <60 group than in the \geq
118	60 group. In this first group, diabetes, kidney disease, and immunosuppression had the highest
119	ORs; whereas in the ≥ 60 group, the comorbidities with the highest ORs were kidney and
120	respiratory diseases (Fig. 4).
121	The logistic regression allowed us to assign a score to the comorbidities and their combinations,
122	from one (lower probability of a severe outcome) to eight (high probability of a severe outcome)
123	for both age groups. These scores were ordered into three categories of low, medium, and high
124	risk, based on the incidence of death from COVID-19. It can be observed that the highest score is

found with the combination of diabetes and kidney disease or the combination of 3 or more comorbidities.

Figure 4: Odds ratios for comorbidities in the <60 group and ≥ 60 age group.

128

130

Table 1: Score assigned to the different comorbidities based on the probability of death when

infected by COVID-19 (multivariate logistic regression) and the fatality rate.

Score range		Comorbidities	Assigned score
Low Score	Probability <0.02 Fatality rate =0.5 n=458076	Cardiovascular disease Respiratory disease	1
Medium Score	Probability =0.02-0.04	Cardiovascular disease + Respiratory disease	2
	Fatality rate =4.0	Immunosuppression	2.5
		Kidney disease	3
	n=12352	Diabetes	3.5
High Score	Probability ≥0.05	Immunosuppression + Respiratory disease	4
	Fatality rate =7.0	Kidney disease + Respiratory disease	5
	n=5129	Diabetes + Respiratory disease	5.5
		lmmunosuppression + Cardiovascular disease	6

Cardiovascular disease + Renal disease	6.5
Diabetes + cardiovascular disease	7
Immunosuppression + Kidney disease	7.5
Diabetes + Kidney disease or ≥ 3 comorbidities	8

≥60 group			
Score rang	ge	Comorbidities	Assigned score
Low	Probability <0.17	Cardiovascular disease	1
Score	Fatality rate =9.9	Immunosuppression	1
	n=65466	Diabetes	1
Medium	Probability 0.17-	Respiratory disease	2
Score	0.29 Fatality rate=	Immunosuppression + Cardiovascular disease	2.5
	20.7	Kidney disease	3
	n=7801	Cardiovascular disease + diabetes	3.5
		Diabetes + Immunosuppression	4
		Cardiovascular disease + Respiratory disease	4.5
		Immunosuppression + Respiratory disease	5
		Cardiovascular disease + Kidney disease	5.5
		Diabetes + Respiratory disease	6
		Immunosuppression + Kidney	6.5

		disease	
High	Probability ≥0.29	Renal disease + Respiratory	7
Score	Fatality rate =	disease	
	30.1	Diabetes + Kidney disease or ≥ 3 comorbidities	8
	n=909	5 comorbidities	

132

133

134 Discussion

Since the beginning of the COVID-19 pandemic in December 2019, the reported case fatality rate has varied. Early estimates from small cohorts of hospitalized patients indicated a fatality rate of 15%; later and with more data, the percentage of deaths fell from 11% to 4.3% and finally to 3.4%.⁸ In addition, 81% of patients with COVID-19 have a mild illness and never require hospitalization.⁹ Therefore, for a better understanding of the causes that lead to severe results of COVID-19, in this retrospective cohort study, we analyzed risk factors for death in individuals with COVID-19 in a large database from Brazil with a fatality rate of 2.1%.

Older age has been reported by several authors as an important factor associated with the severity of the disease or fatality in patients with COVID-19.^{4,5,10} In accordance with this, we found a higher fatality rate in patients older than 60 years of age.

It is important to highlight the relevance of age-stratified analyses when examining the association between comorbidities and fatality with COVID-19.⁵ In our study, the odd ratio (OR) values for comorbidities varied depending on age group. In the <60 group, both higher ORs and a higher AUC value were observed compared to those obtained for the \geq 60 group. This suggests that the comorbidities considered are able to better explain the fatality from COVID-19 in the <60 group than in the ≥ 60 group. Therefore, the comorbidities seem to have an important impact on death in the <60 group, while in the ≥ 60 group the comorbidities might play a minor role in death from COVID-19. This suggests that the main risk factor in the older group is age itself, which is consistent with previous findings for Brazilians patients.³

Diabetes was the most frequent comorbidity and had the highest OR value in the <60. Patients 154 155 who presented diabetes as comorbidity, reached a fatality rate of 0.5% and 19% in the <60 group and \geq 60 group, respectively (Fig. 2). Worth mentioning, Brazil is one of the countries with more 156 diabetes cases in the world, being the estimated prevalence of 11.9 % (95 % CI 7.7–17.8).¹¹ The 157 158 evolution of COVID-19 has shown to be more severe in patients with diabetes and metabolic dysfunction.¹² Recent data suggests that COVID-19 could precipitate acute metabolic 159 complications of diabetes, such as diabetic ketoacidosis and hyperglycemia. The potential 160 mechanisms that may increase susceptibility to severe COVID-19 in patients with diabetes 161 include: 1) higher affinity cell binding and effective entry of the virus, 2) decreased viral 162 clearance, 3) decreased T cell function, 4) increased susceptibility to hyperinflammation and 163 cytokine storm syndrome, and 5) presence of cardiovascular diseases.¹³ This becomes more 164 165 relevant when considering that the most frequent combination of comorbidities included diabetes 166 and cardiovascular disease, with a fatality rate of 6% and 20% in the <60 group and \geq 60 group, respectively. 167

Another important risk factor is kidney disease. In the ≥ 60 group, this comorbidity together with respiratory disease presented the highest ORs. Moreover, the combination of diabetes with kidney disease caused the highest fatality rates. Since diabetes is the main cause of chronic kidney disease,¹⁴ patients with these two comorbidities can represent diabetic patients in a more severe stage of the disease or without adequate medical care. Interestingly, the human kidney has
been reported to be a target for SARS-CoV-2¹⁵; however, it remains controversial whether
SARS-CoV-2 causes acute kidney injury.¹⁶

There is a wide spectrum of immunosuppressed patients, including patients with cancer, solid 175 176 organ transplant recipients, those taking antirheumatic drugs, primary immunodeficiency, and HIV infection. We found that in both age groups, immunosuppression was a risk factor 177 178 associated with death from COVID-19. However, this should be interpreted with caution since the database did not allow to determine precisely the underlying cause of the immunosuppression 179 180 and because there is controversy about the role immunosuppression in COVID-19. Previous research indicates that patients with cancer and solid organ transplant recipients may have a 181 higher risk of developing more severe COVID-19.^{17,18} Nonetheless, immunosuppressed adults 182 with no further comorbidities might not be likely to have a severe clinical outcome.¹⁸ This 183 contradiction may be because the host's immune response is an important factor contributing to 184 the severity of COVID-19, through a dysregulation of innate immunity or an excessive 185 inflammatory response.¹⁹ Thus, immunosuppression, as a sole comorbidity, probably does not 186 187 determine a severe outcome.

As has been shown in this study, there are comorbidities that increase the probability of severe COVID-19. Therefore, they should be considered in case management. Concerning this, we assigned a score to each comorbidity to provide a possible order of priority. Based on the analysis of this large database, there are small subgroups of cases that carry an exceedingly high risk of death due to COVID-19. It is important to understand the limitations of this study when interpreting these results. First, possible selection biases cannot be ruled out due to the reduction of the data file. Second, the data come from all the states of Brazil, but might not be representative of the entire population, and the generalizability of the results beyond this cohort is unclear. However, it is worth noting the high number of cases analyzed and that the proportion of the comorbidities in the database (n=549733) is similar to in the original data file (n=8056794).

In conclusion, we demonstrate that diabetes, kidney disease, respiratory disease, cardiovascular disease, and immunosuppression are risk factors related to death from COVID-19, where age seems to be a determining factor. The combination of comorbidities increases the risk, which must be considered and analyzed for clinical decisions.

- 203 **Competing interests:** The authors declare that they have no competing interests.
- **Funding:** This article did not have any kind of funding.
- 205 **Ethics approval:** The material used was freely available on the website of the Brazilian Ministry
- of Public Health, so it was not necessary to have ethical approval.

207 Supplementary materials: Supplementary material associated with this article can be found in


the online version.


209 **References**


- Hopkins C for SS and E (CSSE) J. COVID-19 Map Johns Hopkins Coronavirus Resource Center. Accessed May 5, 2020. https://coronavirus.jhu.edu/map.html
- Curtis JR, Kross E, Stapleton R. The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019 (COVID-19). *JAMA*. 2020;346(323):1771-1772. doi:10.1056/nejmsa012528.
- Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and regional variations in
 hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. *Lancet*


217		Glob Heal. 2020;8(8):e1018-e1026. doi:10.1016/S2214-109X(20)30285-0.
218 219 220 221	4.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>Lancet</i> . 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
222 223 224 225	5.	Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Med.</i> 2020;17(9):1-11. doi:10.1371/JOURNAL.PMED.1003321.
226 227	6.	Notificações de Síndrome Gripal - Conjuntos de dados - Open Data. Accessed August 1, 2020. https://opendatasus.saude.gov.br/dataset/casos-nacionais
228 229 230	7.	MINISTÉRIO DA SAÚDE Guia de ViGilância EpidemiolóGica EmerGência de Saúde Pública de Importância Nacional Pela Doença Pelo CoronaVíruS 2019. Accessed November 6, 2020. http://www.saude.gov.br/svs
231 232 233	8.	Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. <i>Lancet Infect Dis.</i> 2020;20(7):776-777. doi:10.1016/S1473-3099(20)30244-9.
234 235	9.	Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. <i>Lancet</i> . 2020;395(10229):1014-1015. doi:10.1016/S0140-6736(20)30633-4.
236 237 238 239 240 241 242	10.	Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. <i>Lancet Infect Dis.</i> 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7.
243 244 245	11.	Telo GH, Cureau FV, De Souza MS, Andrade TS, Copês F, Schaan BD. Prevalence of diabetes in Brazil over time: A systematic review with meta-analysis. <i>Diabetol Metab Syndr</i> . 2016;8(1):1-13. doi:10.1186/s13098-016-0181-1.
246 247	12.	The Lancet Diabetes & Endocrinology. COVID-19 and diabetes: a co-conspiracy? <i>Lancet Diabetes Endocrinol</i> . 2020;8(October):801.
248 249	13.	Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. <i>Am J Physiol - Endocrinol Metab.</i> 2020;318(5):E736-E741. doi:10.1152/ajpendo.00124.2020.
250 251	14.	Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L. Chronic kidney disease and diabetes. <i>Maturitas</i> . 2012;71(2):94-103. doi:10.1016/j.maturitas.2011.11.009.
252 253 254	15.	Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, Wang C, Liu L, Liu Y, Liu Y, Wang G, Yuan Z, Ren L, Wu Y, Chen Y. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Publ Online</i> . 2020.
255	16.	Zhou H, Zhang Z, Fan H, Li J, Li M, Dong Y, Guo W, Lin L, Kang Z, Yu T, Tian C, Gui

- Y, Qin R, Wang H, Luo S, Hu D. Urinalysis, but not blood biochemistry, detects the early
 renal-impairment in patients with COVID-19. *SSRN Electron J*. 2020.
 doi:10.1101/2020.04.03.20051722.
- Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far.
 Clin Infect Dis. 2020. doi:10.1093/cid/ciaa863.
- 18. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status
 affecting children and adults in SARS-CoV-2 infection? A systematic review. *J Infect*.
 2020;81(1):e61-e66. doi:10.1016/j.jinf.2020.04.026.
- Abdulamir AS, Hafidh RR. The possible immunological pathways for the variable
 immunopathogenesis of COVID—19 infections among healthy adults, elderly and
 children. *Electron J Gen Med*. 2020;17(4):1-4. doi:10.29333/ejgm/7850.









- >=60 years old
- > 60 years old

Respiratory disease -Respiratory disease -ഗ Cardiovascular disease -Comorbiditie Cardiovascular disease -Inmunossuppresed -Inmunossuppresed -Kidnev disease -Kidney diease -**Diabetes** Diabetes ·

